Sunshine Biopharma's Anticancer Drug Candidate, Adva-27a, Is Unaffected by the Recent Supreme Court Ruling on Patentability o...
June 19 2013 - 08:00AM
Marketwired
Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company
focused on the research, development and commercialization of drugs
for the treatment of various forms of cancer, today announces that
its operations are unaffected by the recent Supreme Court ruling on
patentability of Human Genes. Sunshine Biopharma's anticancer drug
development program is not dependent on and does not utilize human
genes. Sunshine Biopharma had previously reported that Adva-27a is
capable of effectively killing aggressive or multidrug resistant
cancer cells including Breast Cancer cells (MCF-7/MDR), Small-Cell
Lung Cancer cells (H69AR), Uterine Sarcoma cells (MES-SA/Dx5), and
Pancreatic Cancer cells (Panc-1).
"Sunshine Biopharma is not in the business of patenting human
genes or copies thereof, such as cDNA. We patent small molecules
for use as chemotherapeutics in the treatment of cancer," said Dr.
Steve N. Slilaty, CEO of Sunshine Biopharma.
About Sunshine Biopharma Inc. Sunshine
Biopharma is an early stage pharmaceutical company focused on the
research, development and commercialization of drugs for the
treatment of various forms of cancer. Sunshine Biopharma recently
announced that it has initiated IND-Enabling studies for its lead
antitumor compound, Adva-27a, which is currently targeted for
multidrug resistant cancer.
Safe Harbor Forward-Looking Statements To
the extent that statements in this press release are not strictly
historical, including statements as to revenue projections,
business strategy, outlook, objectives, future milestones, plans,
intentions, goals, future financial conditions, future
collaboration agreements, the success of the Company's development,
events conditioned on stockholder or other approval, or otherwise
as to future events, such statements are forward-looking, and are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks
and uncertainties that could cause actual results to differ
materially from the statements made.
For Additional Information Contact: Camille Sebaaly CFO
Sunshine Biopharma Inc. Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com www.sunshinebiopharma.com